TP53 and AL amyloidosis: Feng et al. reported that NEK2 deficiency inhibit tumor proliferation and enhance the drug sensitivity against multiple myeloma, and NEK2 could act as a target of precision therapy in multiple myeloma with p53 abnormalities [37].